LENZ Therapeutics, Inc. filings document the company’s transition from ophthalmic product development to commercialization of VIZZ (aceclidine ophthalmic solution) 1.44% for presbyopia in adults. Form 8-K disclosures cover financial results, FDA approval and U.S. availability of VIZZ, product launch updates, safety-related communications, and capital-raising activity under an at-the-market sales agreement.
The company’s proxy and governance materials address shareholder voting matters, executive and board governance, material agreements, capital-structure disclosure, and operating and financial results. The filing record also captures regulatory and commercial disclosures tied to VIZZ, including product approval, launch-stage operations, financing transactions, and risk-related information relevant to a pharmaceutical company commercializing an ophthalmic prescription product.
LENZ Therapeutics, Inc. reported third-quarter 2026 total revenue of $3.384 million, versus $12.5 million a year earlier, as license revenue was $785,000 versus $12.5 million. VIZZ product sales were $2.599 million, up 50% from Q2. Net loss widened to $30.969 million from $16.700 million.
Cash, cash equivalents and marketable securities totaled $197.3 million as of September 30, 2026. The board approved a reorganization that reduces headcount by approximately 75% to approximately 40 full-time employees. LENZ expects projected 2027 annualized operating expenses to fall by more than 50%, targeting $70 million to $75 million excluding stock-based compensation. The reorganization is expected to be substantially completed in Q4 2026, with approximately $5 million in non-recurring charges, substantially all expected in that quarter.
Evert Schimmelpennink will transition from President and CEO and leave the board effective December 1, 2026; Daniel Chevallard will become Interim President and CEO while retaining his CFO role. Schimmelpennink will serve as a strategic adviser through December 31, 2026. Subject to the separation agreement’s conditions, he is eligible for lump-sum payments of $731,400 and $309,016.50.
BlackRock Portfolio Management LLC reported beneficial ownership of 1,645,489 shares of LENZ Therapeutics, Inc. common stock, equal to 5.2% of the class. The report attributes the securities to certain business units of BlackRock, Inc. and its subsidiaries and affiliates, excluding other business units whose holdings are disaggregated. It lists sole voting power over 1,395,487 shares and sole dispositive power over 1,645,489 shares, with no shared voting or dispositive power.
LENZ Therapeutics, Inc. is the issuer for which Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander, as reporting persons, each listed potential beneficial ownership of 1,159,987 shares, or 3.7% of the class. Each reported shared voting and dispositive power over 1,159,987 shares, with zero sole voting and dispositive power.
The disclosure says the shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC and Israel A. Englander. It states that the disclosure alone is not an admission of beneficial ownership by the reporting persons.
LENZ Therapeutics, Inc. (LENZ) is reported in this Schedule 13G/A as having approximately 1,783,202.25 shares of common stock beneficially owned by FMR LLC, representing 5.7% of the class. FMR LLC is a Delaware entity filing as a parent holding company with affiliated subsidiaries.
The filing also reports that Abigail P. Johnson has beneficial ownership over the same 1,783,202.25 shares on a sole dispositive basis, with no voting or dispositive power shared with others. One or more other persons may receive dividends or sale proceeds, but no other person has more than 5% of the outstanding common stock.
LENZ Therapeutics, Inc. reported its first full periods of commercialization for VIZZ, its FDA‑approved eye drop for presbyopia. For the three months ended June 30, 2026, revenue was $5.5 million, including $1.7 million of VIZZ product sales and $3.8 million of license revenue from ex‑U.S. partnerships.
The company recorded a quarterly net loss of $31.9 million and a six‑month net loss of $73.4 million, driven largely by selling, general and administrative expenses of $84.3 million for the first half as commercial activities expanded. Research and development expenses were minimal as major trials had been completed.
As of June 30, 2026, cash, cash equivalents and marketable securities totaled $220.0 million, total assets were $236.6 million, and stockholders’ equity was $219.3 million. The company had an accumulated deficit of $300.5 million but believes existing liquidity will fund operations for at least 12 months.
LENZ Therapeutics reported second quarter 2026 results highlighted by initial commercialization of VIZZ, its FDA-approved aceclidine eye drop for presbyopia. Total Q2 2026 revenue was $5.5 million, including $1.7 million in product sales from approximately 27,000 VIZZ packs and $3.8 million in license revenue driven by ex-U.S. partnership milestones.
Cash, cash equivalents and marketable securities totaled $220.0 million as of June 30, 2026. Commercial investment weighed on profitability: selling, general and administrative expenses rose to $39.4 million in Q2, leading to a Q2 net loss of $31.9 million, or $1.02 per share, compared with a $14.9 million loss a year earlier.
The company expanded its global strategy with new or advanced arrangements in Canada, Australia, New Zealand, Greater China and the Middle East, tied to potential milestones of up to $65 million from Théa and $85.0 million from the Everest/CORXEL arrangement, plus tiered royalties. Management also launched a telehealth channel and national advertising to support U.S. uptake and reports strong early refill behavior, with key cohorts tracking toward five VIZZ packs per year.
LENZ Therapeutics, Inc. reports changes to its Board of Directors. On June 30, 2026, director Zach Scheiner resigned from the Board and all its committees, effective immediately.
The company states his resignation did not arise from any dispute or disagreement over its operations, policies or practices. On the same date, the Board reduced its size to six members and appointed Jeff George to the Audit Committee, which now consists of Shelley Thunen, Frederic Guerard and Jeff George.
LENZ Therapeutics, Inc. Schedule 13G discloses that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared voting and dispositive power over 1,603,512 shares of Common Stock, representing 5.1% of the class as shown on the cover page dated 06/23/2026.
The filing states these shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and related managers; a joint filing agreement dated June 25, 2026 is attached.
LENZ Therapeutics reported an option grant tied to RA Capital–affiliated entities. A stock option for 22,100 shares of common stock was awarded with an exercise price of $6.63 per share and an expiration date of June 15, 2036.
All 22,100 option shares vest on the earlier of June 15, 2027 or the next annual stockholder meeting, subject to Dr. Scheiner continuing as an Outside Director under the company’s policy. Under Dr. Scheiner’s arrangement with RA Capital, any net cash or stock from exercising this option is turned over to RA Capital for the benefit of its funds and account, and the reporting persons disclaim beneficial ownership beyond any pecuniary interest.
LENZ Therapeutics director George Jeffrey P. received a stock option grant covering 22,100 shares of common stock. The option has an exercise price of $6.63 per share and expires on June 15, 2036.
All 22,100 shares vest in a single tranche, provided he continues to serve as an Outside Director, on the earlier of June 15, 2027 or the date of the next annual meeting of stockholders. Following this grant, he holds options for 22,100 shares directly.